Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

KOZMARY, STEVEN

NPI: 1659337459 · LAS VEGAS, NV 89102 · Interventional Pain Medicine Physician · NPI assigned 04/21/2006

$230K
Total Medicaid Paid
3,413
Total Claims
3,043
Beneficiaries
6
Codes Billed
2018-01
First Month
2019-01
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 3,379 $228K
2019 34 $2K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,719 1,557 $125K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 469 427 $48K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 992 850 $37K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 157 137 $11K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 47 44 $7K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 29 28 $3K